Nel ASA's Revenue Conversion Challenge Intensifies Ahead of Q1 Report

Nel ASA faces a critical test as it reports Q1 figures. Investors watch for progress in converting its NOK 1.3B order backlog into sales amid analyst caution and internal restructuring.

The spotlight is firmly on Nel ASA’s ability to turn a robust order book into actual sales as the Norwegian hydrogen specialist prepares to release its first-quarter figures. The company’s stock, having climbed roughly 21% year-to-date to €0.23, reflects a market warming to its potential, yet the upcoming financial report presents a critical test of execution.

Investor focus will zero in on the persistent gap between orders and revenue. In the final quarter of 2025, order intake skyrocketed by 364% thanks to a major PEM electrolyser contract. Paradoxically, revenue from customer contracts plummeted by 20% in the same period. The core task for CEO Håkon Volldal and his team is to begin converting a year-end order backlog exceeding NOK 1.3 billion into recognized income. The previous quarter concluded with an operating EBITDA loss of NOK 36 million, underscoring the urgency.

A recent order provides a glimmer of progress. Nel’s US subsidiary secured a $7 million contract from Mesure Process, a part of Synqo Energies, for containerized PEM electrolysers destined for hydrogen refueling stations and industrial use. This repeat business from an existing client is viewed within the industry as a strong endorsement of technology reliability. The systems are scheduled for commissioning in 2027.

Internally, management is restructuring its incentive scheme to align with this conversion challenge. The annual general meeting approved a shift to a performance-based share unit (PSU) plan, scrapping the old stock option program for executives. Both CEO Volldal and CFO Kjell Christian Bjørnsen have voluntarily forfeited existing options. Their future equity awards are now tied to achieving stringent corporate performance targets over a three-year period.

Analysts, however, remain cautious ahead of the report. Major institutions have adopted a defensive stance, with Morgan Stanley slashing its price target to NOK 2.00 and Citi reducing its fair value estimate to NOK 2.40. Both banks maintain a "Hold" rating, advising investor patience.

Beyond immediate finances, Nel faces a potential balance sheet adjustment. The company is currently reviewing the book values of two idled production lines at its Herøya facility, with market observers anticipating concrete statements on possible write-downs in the quarterly release.

The long-term investment thesis continues to hinge on technological advancement. Nel is progressing with a new pressurized alkaline electrolyser platform, which successfully completed testing in Herøya. A commercial launch is targeted for the first half of 2026, with large-scale deliveries expected from 2027. The European Union has pledged grant funding of up to €135 million to support the industrialization of this technology, covering a significant portion of the investment needed for a planned annual capacity of four gigawatts.

Financially, the company enters this pivotal period with a solid liquidity buffer of approximately NOK 1.6 billion. Management will present the quarterly results and face investor questions in a virtual presentation scheduled for Wednesday at 08:00 CET. Clear signals that the burgeoning order backlog is starting to generate revenue, coupled with definitive updates on the new alkaline platform, will be essential to sustain the stock's recent momentum.